Waldenstrom Macroglobulinemia Market Positioned for Accelerated Development Through 2034, DelveInsight Finds

DelveInsight's "Waldenstrom Macroglobulinemia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Waldenstrom Macroglobulinemia, historical and forecasted epidemiology as well as the Waldenstrom Macroglobulinemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Waldenstrom Macroglobulinemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Waldenstrom Macroglobulinemia Market Forecast
https://www.delveinsight.com/sample-request/waldenstrom-macroglobulinemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Waldenstrom Macroglobulinemia Market Report:
• The Waldenstrom Macroglobulinemia market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• Among the EU4 and the UK, the United Kingdom recorded the largest market size, amounting to roughly USD 16.4 million, followed by Germany, while XX had the smallest market size in 2023.
• In 2023, roughly 3,190 new cases of Waldenström macroglobulinemia were reported in the seven major markets (7MM), with the United States representing 40% of these cases, followed by France.
• The US FDA has granted approval to IMBRUVICA (ibrutinib) from Janssen/AbbVie for the treatment of Waldenström macroglobulinemia. The development pipeline for WM is quite limited, with only a handful of companies advancing their candidates through clinical trials.
• The MYD88 L265P mutation, found in more than 85% of patients with Waldenström macroglobulinemia, serves as a crucial diagnostic marker. This mutation leads to the constant activation of Bruton's tyrosine kinase (BTK) via the interleukin-1 receptor signaling pathway, which is essential for B-cell receptor (BCR) signaling. This signaling pathway regulates immune responses, cell proliferation, and cell survival, all of which are processes directly associated with B-cell lymphoproliferative disorders such as Waldenström macroglobulinemia.
• Key Waldenstrom Macroglobulinemia Companies: AbbVie, Cellectar Biosciences, TG Therapeutics, Eli Lilly and Company, Celgene Corp., AstraZeneca, ADC Therapeutics S.A., Amgen, Merck Sharp & Dohme LLC, Onyx Therapeutics, Inc., BeiGene, GlaxoSmithKline, Beijing InnoCare Pharma, Millennium Pharma, Janssen, LP, and others
• Key Waldenstrom Macroglobulinemia Therapies: Venetoclax, CLR 131, Umbralisib, Pirtobrutinib, Revlimid, Acalabrutinib, Loncastuximab Tesirine, ABT199, Carfilzomib + Ibrutinib, Rituximab, Carfilzomib, BGB-11417, Ofatumumab, ICP-022, Bortezomib (Velcade), Daratumumab, and others
• The Waldenstrom Macroglobulinemia epidemiology based on gender analyze that males are more affected by WM than females, experiencing two times the risk than females
• The Waldenstrom Macroglobulinemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Waldenstrom Macroglobulinemia pipeline products will significantly revolutionize the Waldenstrom Macroglobulinemia market dynamics.

Waldenstrom Macroglobulinemia Overview
Waldenstrom Macroglobulinemia (WM) is a rare type of non-Hodgkin lymphoma, a cancer that starts in white blood cells called lymphocytes. It is characterized by the production of an abnormal protein known as monoclonal immunoglobulin M (IgM) antibody by cancerous B cells, leading to a thickening of the blood. This condition typically affects older adults.

Get a Free sample for the Waldenstrom Macroglobulinemia Market Report:
https://www.delveinsight.com/report-store/waldenstrom-macroglobulinemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Waldenstrom Macroglobulinemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Waldenstrom Macroglobulinemia Epidemiology Segmentation:
The Waldenstrom Macroglobulinemia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Waldenstrom Macroglobulinemia
• Prevalent Cases of Waldenstrom Macroglobulinemia by severity
• Gender-specific Prevalence of Waldenstrom Macroglobulinemia
• Diagnosed Cases of Episodic and Chronic Waldenstrom Macroglobulinemia

Download the report to understand which factors are driving Waldenstrom Macroglobulinemia epidemiology trends @ Waldenstrom Macroglobulinemia Epidemiology Forecast
https://www.delveinsight.com/sample-request/waldenstrom-macroglobulinemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Waldenstrom Macroglobulinemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Waldenstrom Macroglobulinemia market or expected to get launched during the study period. The analysis covers Waldenstrom Macroglobulinemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Waldenstrom Macroglobulinemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Waldenstrom Macroglobulinemia Therapies and Key Companies
• Venetoclax: AbbVie
• CLR 131: Cellectar Biosciences
• Umbralisib: TG Therapeutics
• Pirtobrutinib: Eli Lilly and Company
• Revlimid: Celgene Corp.
• Acalabrutinib: AstraZeneca
• Loncastuximab Tesirine: ADC Therapeutics S.A.
• ABT199: AbbVie
• Carfilzomib + Ibrutinib: Amgen
• Rituximab: Merck Sharp & Dohme LLC
• Carfilzomib: Onyx Therapeutics, Inc.
• BGB-11417: BeiGene
• Ofatumumab GlaxoSmithKline
• ICP-022: Beijing InnoCare Pharma
• Bortezomib (Velcade): Millennium Pharma
• Daratumumab: Janssen, LP

Discover more about therapies set to grab major Waldenstrom Macroglobulinemia market share @ Waldenstrom Macroglobulinemia Treatment Market
https://www.delveinsight.com/sample-request/waldenstrom-macroglobulinemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Waldenstrom Macroglobulinemia Market Strengths
• Robust pipeline of emerging therapies in different classes of drugs
• Scientific advances and identification of novel biomarkers for disease diagnosis and treatment such as CXCR4 mutations
• Strategic partnerships including mergers and acquisitions, co-development deals, and licensing deals among active players

Waldenstrom Macroglobulinemia Market Opportunities
• There are no curative therapies approved for Waldenstrom Macroglobulinemia
• Future genomic profiling may lead to the identification of potential biomarkers to improve early detection and diagnosis of Waldenstrom Macroglobulinemia
• Development of novel therapeutic targets like BCL-2 inhibitors, etc
• Support initiatives by regulatory authorities to fasten drug development like Priority Review, Real-time Oncology Review, Project Orbis, etc

Scope of the Waldenstrom Macroglobulinemia Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Waldenstrom Macroglobulinemia Companies: AbbVie, Cellectar Biosciences, TG Therapeutics, Eli Lilly and Company, Celgene Corp., AstraZeneca, ADC Therapeutics S.A., Amgen, Merck Sharp & Dohme LLC, Onyx Therapeutics, Inc., BeiGene, GlaxoSmithKline, Beijing InnoCare Pharma, Millennium Pharma, Janssen, LP, and others
• Key Waldenstrom Macroglobulinemia Therapies: Venetoclax, CLR 131, Umbralisib, Pirtobrutinib, Revlimid, Acalabrutinib, Loncastuximab Tesirine, ABT199, Carfilzomib + Ibrutinib, Rituximab, Carfilzomib, BGB-11417, Ofatumumab, ICP-022, Bortezomib (Velcade), Daratumumab, and others
• Waldenstrom Macroglobulinemia Therapeutic Assessment: Waldenstrom Macroglobulinemia current marketed and Waldenstrom Macroglobulinemia emerging therapies
• Waldenstrom Macroglobulinemia Market Dynamics: Waldenstrom Macroglobulinemia market drivers and Waldenstrom Macroglobulinemia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Waldenstrom Macroglobulinemia Unmet Needs, KOL's views, Analyst's views, Waldenstrom Macroglobulinemia Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.